Actively Recruiting

Early Phase 1
Age: 45Years +
All Genders
NCT06961630

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

Led by NYU Langone Health · Updated on 2026-04-06

50

Participants Needed

1

Research Sites

77 weeks

Total Duration

On this page

Sponsors

N

NYU Langone Health

Lead Sponsor

N

National Heart, Lung, and Blood Institute (NHLBI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this pilot study is to assess enrollment feasibility of a randomized trial of direct oral anticoagulant and high-intensity statin therapy versus usual care in patients with Myocardial Injury after Noncardiac Surgery (MINS). The primary aims of this study are to assess feasibility, study drug adherence, and optimize study design (entry criteria, study endpoints, sample size calculation, site selection) and recruitment strategies for the future multicenter randomized clinical trial studying biomarker-based care in post-operative patients at elevated cardiovascular (CV) risk.

CONDITIONS

Official Title

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

Who Can Participate

Age: 45Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 45 years or older
  • Underwent major non-cardiac surgery requiring at least one overnight hospital stay within the past 14 days
  • Experienced myocardial injury after non-cardiac surgery, defined by post-operative troponin levels at or above the 99th percentile upper reference limit with a rise or fall greater than 20% indicating acute injury
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • Expected survival less than 6 months
  • Presence of hemorrhagic disorder
  • Surgeon deems it unsafe to start low-dose anticoagulation within 14 days after surgery
  • Need for oral anticoagulation at discharge
  • Need for dual antiplatelet therapy at discharge
  • Currently receiving or planned to receive moderate or high-intensity statin therapy
  • Contraindication to high-intensity statin
  • Contraindication to rivaroxaban
  • End-stage kidney disease requiring hemodialysis
  • Acute liver failure or decompensated cirrhosis
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

NYU Langone Health

New York, New York, United States, 10016

Actively Recruiting

Loading map...

Research Team

N

Nathaniel Smilowitz

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction | DecenTrialz